Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 229

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Open access
Singh, Siddharth, Facciorusso, Antonio, Dulai, Parambir S., Jairath, Vipul, Sandborn, William J. · 2020 · Clinical Gastroenterology and Hepatology

Abstract

Background and Aims: We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor-α (TNFα) antagonists, biologic agents that do not inhibit TNFα, tofacitinib, and immunosuppressive agents in inflammatory bowel diseases (IBD). Methods: Through a systematic search until March 18, 2018, we included 15 observational studies (>500 person-years) in patients with IBD treated with TNFi, non-TNFi biologics, tofacitinib and/or IS monotherapy (thiopurines, methotrexate), reporting the risk of serious infections. Studies reporting active comparators were included, to allow appropriate comparative synthesis. We performed random effects meta-analysis and estimated relative risk (RR) and 95% CIs. Results: Compared to monotherapy with a TNFα antagonist, risk of serious infection increased with the combination of a TNFα antagonist and an immunosuppressive agent (in 6 cohorts; RR, 1.19; 95% CI, 1.03–1.37), with a TNFα antagonist and corticosteroids (in 4 cohorts; RR, 1.64; 95% CI, 1.33–2.03), or with all 3 drugs (in 2 cohorts; RR, 1.35; 95% CI, 1.04–1.77); there was minimal heterogeneity among studies. In contrast, monotherapy with an immunosuppressive agent was associated with a lower risk of serious infections than monotherapy with a TNFα antagonist (7 cohorts; RR, 0.61; 95% CI, 0.44–0.84) or a TNFα antagonist with an immunosuppressive agent (2 cohorts; RR, 0.56; 95% CI, 0.39–0.81). Infliximab-based therapy was associated with lower risk of serious infections as compared to adalimumab-based therapy in patients with ulcerative colitis (4 cohorts; RR, 0.57 [0.33–0.97]), but not Crohn’s disease (4 cohorts; RR, 0.91 [0.49–1.70]). Few data are available on the comparative safety of biologic agents that do not inhibit TNFα and tofacitinib. Conclusion: Combination therapies for IBD that include TNFα antagonists, especially with corticosteroids, are associated with higher risk of serious infection, whereas monotherapy with an immunosuppressive agent is associated with lower risk, compared to monotherapy with a TNFα antagonist. Studies are needed to evaluate the comparative safety of biologic agents that do not inhibit TNFα and tofacitinib for treatment of IBD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2019.02.044

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Singh, S., Facciorusso, A., Dulai, P. S., Jairath, V., & Sandborn, W. J.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2020-01
Volume
18
Issue
1
Pages
69-81.e3
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2920997743
Cited by
229
References
2
FWCI
4.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.